| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | basement membrane | 한글 | 바닥막, 기저막 |
|---|---|---|---|
| 설명 | 상피세포, 근육세포, 신경조직과 그것들의 바깥쪽 결합조직의 경계에 있는 점액다당질과 단백질로 구성된 얇은 막. 기초막 또는 경계막이라고도 한다. 두께는 50~80nm이다. 기저막은 20~30nm 간격으로 늘어선 족세포로 된 상피세포의 3층으로 되어 있고, 분자량 40,000~60,000의 물질을 투과할 수 있게 한다. 또한 표피와 진피의 경계로 영양을 공급하는 기지 역할을 한다. 주로 섬유를 포함하여 다당류로 되어 있는데, 현저하게 발달되어 있는 부분과 그렇지 않은 부분이 있다. 비점막에서는 점막상피의 밑에 발달한 기저막이 있다. 이 막 위에 청각수용세포인 털세포를 갖는 코르티기관이 존재한다. 기저막은 전제가 음전기 성질을 가지고 있어 양전기를 가진 물질이 투과하기 쉽다. 기저막이 팽화하거나 밀도가 낮아지면 단백질이 통과하여 단백뇨를 일으키고, 기저막에 균열-파괴 등이 일어나면 적혈구 등의 혈액 고형성분이 투과하여 혈뇨가 된다. |
||
| 영문 | hyaline membrane disease | 한글 | 유리질막병 |
|---|---|---|---|
| 설명 | 허파 성숙도의 미숙으로 허파꽈리를 팽창시키는 물질(표면활성제)이 부족하여 호흡곤란이 초래되는 병으로서 미숙아에 호발하는데, 출생시 임신기간보다도 허파 성숙 정도가 더 관여된다. 단일 병으로서는 사망률이 가장 높으며(약 30%), 신생아의 대표적인 병이다. 임상적으로는 미숙아, 생후 6~8시간내 호흡곤란증세 출현과 생후 24~48시간의 증상 악화, 생후 2~3일간 인공적으로 산소를 공급하지 않으면 호흡을 계속시킬 수가 없으며 점점더 산소의 공급 의존도가 높아지며, 동맥혈액속의 산소농도가 내려가고 이산화탄소의 농도가 높으며, 흉부 방사선 소견을 참작하여 진단한다. 환아는 숙련된 간호 인력과 첨단 의료 장비가 설치된 신생아 집중 치료실에서 치료하여야 한다. 예후는 증세의 경중에 따라 다르고 사망률은 30~50% 된다. 어떤 아기에 있어서는 치료 후에 눈이나 기관지허파 계통에 장애를 일으키는 산소중독증이 보고되고 있다. |
||
| 영문 | plasma membrane | 한글 | 형질막 |
|---|---|---|---|
| 설명 | 원형질 표면을 덮는 엷은막. 두께는 5~25μm이다. 광학현미경으로는 관찰할 수 없지만 전자현미경으로 관찰이 가능하다. 원형질막의 분자구조는 레시틴이나 콜레스테롤 등의 표면 활성물질 분자가 2분자층으로 그 표면에 배열되며, 이것을 각 1분자층의 단백질 분자가 양쪽에서 샌드위치한 단위막 구조이다. 전자현미경적으로 이 단위는 암-명-암의 3층(각 약 20nm)으로 구별된다. 원형질의 투과성에 중요한 구실을 하며, 생리상태가 변하면 그 투과성도 신속히 변한다. 또, 손상이 되면 쉽게 새로 형성된다. |
||
| SCM | Schwann cell membrane; sensation, circulation, and motion; Society of Computer Medicine; soluble cyt... |
|---|---|
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| PROM | 1) Premature Rupture of Amniotic Membrane; < Labor Onset 2) Preterm Ruptu... |
| BLM | bilayer lipid membrane; bimolecular liquid membrane; bleomycin; buccolinguomasticatory |
| CRLR | Calcitonin Receptor-Like Receptor |
|---|---|
| EGF-receptor | Epidermal Growth Factor receptor |
| IRR | Insulin receptor- related receptor |
| alpha 2MR/LRP | alpha (2)-macroglobulin receptor/low density lipoprotein receptor-related protein |
| ORL1 | opioid receptor like receptor |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
|---|---|
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |
| cAMP receptor protein | catabolite (gene) activator protein |
| GABA receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| p60 tumour necrosis factor receptor-associated kinase | <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor Registry number: EC 2.7.10.- Synonym: p60 tnf receptor-associated kinase, p60-trak (26 Jun 1999) |
| gamma aminobutyric acid receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| GAP-1 receptor tyrosine kinase | <enzyme> Similar to rasGTPase-activating proteins; inhibits signaling activity of let-60; amino acid sequence given in first source Registry number: EC 2.7.1.- Synonym: gap-1 gene product, gap-1 protein (26 Jun 1999) |
| gene rearrangement, alpha-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, beta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|